Evaluation of aminoglycosides utilization in intensive care units of a teaching hospital in southern Iran
Background: Inappropriate use of antimicrobial agents is one of the most important factors in inducing resistance and prolonged hospitalization as well as increase in patient mortality rate.
Objective: The aim of this study was to evaluate aminoglycosides (AGs) usage pattern at intensive care units (ICUs) of Nemazee hospital Shiraz, Iran.
Methods: In this cross-sectional study, the usage pattern of AGs was evaluated during 32 months. Guidelines for AGs usage were approved by the drug and therapeutic committee of the hospital, and criteria were developed to assess 11 parameters involving AGs therapy, such as proper indication for the use of the drug, dosage and duration of therapy. Clinical parameters, such as microbial culture and sensitivity, serum creatinine (SCr) and creatinine clearance, and white blood cell count were evaluated.
Results: Ninety-five patients were recruited, 50 male and 45 females. In most patients (64%) the origin of infection was hospital and only in 36% of them, community was the source. Ventilator associated pneumonia (27%), central nervous system (25%) and urinary tract infection (10%) were the most important indications for AGs prescription. Scores of AGs usage at Nemazee hospital was calculated as 5.9 out of 11, which meant that in only 54% of cases AGs prescription was based on guideline proposed by the Department of Clinical Pharmacy of Nemazee Hospital.
Conclusions: Non-adherence to the guidelines occurred frequently in the ICUs of Nemazee hospital. Prescription of loading dose, and AGs level measurement were not done and evaluating microbiological data was often neglected. Incorporating pharmacists in the health care team and holding training programs for physicians and nurses with the goal of raising awareness about the proposed guideline.
Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115(2):462-474. https://doi.org/10.1378/chest.115.2.462
Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1):146-155. https://doi.org/10.1378/chest.118.1.146
Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011;39(1):46-51. https://doi.org/10.1097/CCM.0b013e3181fa41a7
Pillans P, Iedema J, Donovan P, Newbery R, Whitehead V, Halliday C, Sheehy R, Springford A, Patterson T. Outcomes in patients with gram-negative sepsis treated with gentamicin. Ther Adv Drug Saf. 2012 Jun;3(3):109-113. https://doi.org/10.1177/2042098612439495
Hanberger H, Edlund C, Furebring M, C GG, Melhus A, Nilsson LE, Petersson J, Sjolin J, Ternhag A, Werner M, Eliasson E. Rational use of aminoglycosides--review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis. 2013;45(3):161-175. https://doi.org/10.3109/00365548.2012.747694
Kelly KN, Monson JRT. Hospital-acquired infections. Surgery - Oxford International Edition. 2012;30(12):640-4.
Garau J. Impact of antibiotic restrictions: the ethical perspective. Clin Microbiol Infect. 2006;12(Suppl 5):16-24. https://doi.org/10.1111/j.1469-0691.2006.01527.x
Arda B, Sipahi OR, Yamazhan T, Tasbakan M, Pullukcu H, Tunger A, Buke C, Ulusoy S. Short-term effect of antibiotic control policy on the usage patterns and cost of antimicrobials, mortality, nosocomial infection rates and antibacterial resistance. J Infect. 2007;55(1):41-48. https://doi.org/10.1016/j.jinf.2007.02.014
Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, Borok S, Cohen M, Andreassen S, Nielsen AD. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med. 2006;119(11):970-976. https://doi.org/10.1016/j.amjmed.2006.03.034
Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik S. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244(5):379-386. https://doi.org/10.1046/j.1365-2796.1998.00379.x
Vazin A, Karimzadeh I, Zand A, Hatami-Mazinani N, Firouzabadi D. Evaluating Adherence of Health-Care Team to Standard Guideline of Colistin Use at Intensive Care Units of a Referral Hospital in Shiraz, Southwest of Iran. Adv Pharm Bull. 2017;7(3):391-397. https://doi.org/10.15171/apb.2017.047
Organization WH. Introduction to drug utilization research. Geneve: WHO; 2003.
Bae SC. Drug utilization review: economical aspect. J Korean Med Assoc. 2004;47(2):156-60.
Vazin A, Japoni A, Shahbazi S, Davarpanah MA. Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in Iran. Iran J Pharm Res. 2012;11(1):163-170.
Seng JJB, Yong MHA, Peh ZX, Soong JL, Tan MH. Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore. Int J Clin Pharm. 2018;40(5):977-981. https://doi.org/10.1007/s11096-018-0670-4
Leone M, Bourgoin A, Cambon S, Dubuc M, Albanèse J, Martin C. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med. 2003;31(2):462-467. https://doi.org/10.1097/01.CCM.0000050298.59549.4A
Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. https://doi.org/10.1097/01.CCM.0000217961.75225.E9
Paul M, Lador A, Grozinsky‐Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam‐aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;(1):CD003344. https://doi.org/10.1002/14651858.CD003344.pub3
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377. https://doi.org/10.1007/s00134-017-4683-6
Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care. 2007;13(5):592-597. https://doi.org/10.1097/MCC.0b013e32827851d7
Taccone FS, Laterre P-F, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care. 2010;14(2):R53. https://doi.org/10.1186/cc8945
de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. 2014;40(7):998-1005. https://doi.org/10.1007/s00134-014-3276-x
Gálvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38(2):146-151. https://doi.org/10.1016/j.ijantimicag.2011.03.022
Agence française de sécurité sanitaire des produits de santé. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring. Med Mal Infect. 2012;42(7):301-308. https://doi.org/10.1016/j.medmal.2011.07.007
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-c184. https://doi.org/10.1159/000339789
Namazi S, Sagheb MM, Hashempour MM. Usage pattern and serum level measurement of amikacin in the internal medicine ward of the largest referral hospital in the south of Iran: a pharmacoepidemiological study. Iran J Med Sci. 2016;41(3):191-199.
Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012;73(1):27-36. https://doi.org/10.1111/j.1365-2125.2011.04080.x
Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A, Almog Y. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114(3):194-198. https://doi.org/10.1016/s0002-9343(02)01476-6
Vazin A, Birjand MM, Darake M. Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in southern Iran. Drug Healthc Patient Saf. 2018;10:21-26. https://doi.org/10.2147/DHPS.S149451
Robert J, Pean Y, Alfandari S, Bru JP, Bedos JP, Rabaud C, Gauzit R. Application of guidelines for aminoglycosides use in French hospitals in 2013-2014. Eur J Clin Microbiol Infect Dis. 2017;36(7):1083-1090. https://doi.org/10.1007/s10096-016-2892-5
Leong CL, Buising K, Richards M, Robertson M, Street A. Providing guidelines and education is not enough: an audit of gentamicin use at The Royal Melbourne Hospital. Intern Med J. 2006;36(1):37-42. https://doi.org/10.1111/j.1445-5994.2006.01002.x
Mahmoudi L, Niknam R, Mousavi S, Ahmadi A, Honarmand H, Ziaie S, Mojtahedzadeh M. Optimal aminoglycoside therapy following the sepsis: how much is too much? Iran J Pharm Res. 2013;12(2):261-269.
Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs. 2011;71(17):2277-2294. https://doi.org/10.2165/11597020-000000000-00000
Hanberger H, Edlund C, Furebring M, G. Giske C, Melhus Å, Nilsson LE, Petersson J, Sjölin J, Ternhag A, Werner M. Rational use of aminoglycosides - review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis. 2013;45(3):161-175. https://doi.org/10.3109/00365548.2012.747694
Ong DS, van Werkhoven CH, Cremer OL, Thwaites GE, Bonten MJ. Is a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified? Clin Microbiol Infect. 2018;24(2):95-96. https://doi.org/10.1016/j.cmi.2017.09.020
Thuong M, Shortgen F, Zazempa V, Girou E, Soussy CJ, Brun-Buisson C. Appropriate use of restricted antimicrobial agents in hospitals: the importance of empirical therapy and assisted re-evaluation. J Antimicrob Chemother. 2000;46(3):501-508. https://doi.org/10.1093/jac/46.3.501
Shahbazi F, Dashti-Khavidaki S. Colistin: efficacy and safety in different populations. Expert Rev Clin Pharmacol. 2015;8(4):423-448. https://doi.org/10.1586/17512433.2015.1053390
Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N. Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis. Crit Care. 2015;19:63. https://doi.org/10.1186/s13054-015-0795-y
Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, Pfaller M, Edwards Jr JE, Jarvis W, Dawson J. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29(2):253-258. https://doi.org/10.1086/520194
Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014;27(6):573-577. https://doi.org/10.1177/0897190014546836
Atapour A, Elham K, Shahidi S, Najafabadi MM, Hedayati P. Modification of diet in renal disease and Cockraft-Gaultformula accuracy in glomerular filtration rate estimation in Iranian adults. Adv Biomed Res. 2013;2:32. https://doi.org/10.4103/2277-9175.108771
Oliveira JFP, Cipullo JP, Burdmann EA. Aminoglycoside nephrotoxicity. Antimicrob Agents Chemother. 2009;53(7):2887-2891. https://doi.org/10.1128/AAC.01430-08
McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol. 2017;32(11):2015-2025. https://doi.org/10.1007/s00467-016-3533-z
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.